Jones C Michael, Dickinson Tina Marie
Am J Med Sci. 2003 Mar;325(3):149-52. doi: 10.1097/00000441-200303000-00007.
We report 2 patients with polycythemia vera who were demonstrated to be -negative and were unable to tolerate either hydroxyurea or interferon-alpha but who had excellent clinical responses to imatinib mesylate (STI-571). This effect is consistent with the inhibitory effect of imatinib mesylate on c-kit's tyrosine kinase activity as demonstrated by its effectiveness in patients with gastrointestinal stromal tumors.
我们报告了2例真性红细胞增多症患者，他们被证明为阴性，且无法耐受羟基脲或α干扰素，但对甲磺酸伊马替尼（STI-571）有出色的临床反应。这种效应与甲磺酸伊马替尼对c-kit酪氨酸激酶活性的抑制作用一致，这已在胃肠道间质瘤患者中得到证实。
